APRE – aprea therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics [Yahoo! Finance]
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward [Yahoo! Finance]
Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: Stonepine Capital Management, LLC
Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: Sio Capital Management, LLC
Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: HIRSCHMAN ORIN
Form 8-K Aprea Therapeutics, Inc. For: Feb 05
Form 8-K Aprea Therapeutics, Inc. For: Jan 13
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.